Literature DB >> 32170957

Nitrosative Stress and Lipid Homeostasis as a Mechanism for Zileuton Hepatotoxicity and Resistance in Genetically Sensitive Mice.

Dahea You1, Lascelles E Lyn-Cook2, Daniel M Gatti3, Natalie Bell1,4, Philip R Mayeux5, Laura P James6, William B Mattes7, Gary J Larson8, Alison H Harrill1,9.   

Abstract

Zileuton is an orally active inhibitor of leukotriene synthesis for maintenance treatment of asthma, for which clinical usage has been associated with idiosyncratic liver injury. Mechanistic understanding of zileuton toxicity is hampered by the rarity of the cases and lack of an animal model. A promising model for mechanistic study of rare liver injury is the Diversity Outbred (J:DO) mouse population, with genetic variation similar to that found in humans. In this study, female DO mice were administered zileuton or vehicle daily for 7 days (i.g.). Serum liver enzymes were elevated in the zileuton group, with marked interindividual variability in response. Zileuton exposure-induced findings in susceptible DO mice included microvesicular fatty change, hepatocellular mitosis, and hepatocellular necrosis. Inducible nitric oxide synthase and nitrotyrosine abundance were increased in livers of animals with necrosis and those with fatty change, implicating nitrosative stress as a possible injury mechanism. Conversely, DO mice lacking adverse liver pathology following zileuton exposure experienced decreased hepatic concentrations of resistin and increased concentrations of insulin and leptin, providing potential clues into mechanisms of toxicity resistance. Transcriptome pathway analysis highlighted mitochondrial dysfunction and altered fatty acid oxidation as key molecular perturbations associated with zileuton exposure, and suggested that interindividual differences in cytochrome P450 metabolism, glutathione-mediated detoxification, and farnesoid X receptor signaling may contribute to zileuton-induced liver injury (ZILI). Taken together, DO mice provided a platform for investigating mechanisms of toxicity and resistance in context of ZILI which may lead to targeted therapeutic interventions. Published by Oxford University Press on behalf of the Society of Toxicology 2020. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Keywords:  Diversity Outbred; drug-induced liver injury; genetic variability; idiosyncratic hepatotoxicity; zileuton

Mesh:

Substances:

Year:  2020        PMID: 32170957      PMCID: PMC7253212          DOI: 10.1093/toxsci/kfaa037

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  43 in total

1.  Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes.

Authors:  Sathish Kumar Natarajan; Chundamannil E Eapen; Anna B Pullimood; Kunissery A Balasubramanian
Journal:  J Gastroenterol Hepatol       Date:  2006-08       Impact factor: 4.029

2.  Superhydrophobic Coatings with Edible Materials.

Authors:  Wei Wang; Karsten Lockwood; Lewis M Boyd; Matthew D Davidson; Sanli Movafaghi; Hamed Vahabi; Salman R Khetani; Arun K Kota
Journal:  ACS Appl Mater Interfaces       Date:  2016-07-14       Impact factor: 9.229

Review 3.  Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance.

Authors:  Geoffrey A Preidis; Kang Ho Kim; David D Moore
Journal:  J Clin Invest       Date:  2017-03-13       Impact factor: 14.808

4.  Abcb11 deficiency induces cholestasis coupled to impaired β-fatty acid oxidation in mice.

Authors:  Yuanyuan Zhang; Fei Li; Andrew D Patterson; Yao Wang; Kristopher W Krausz; Geoffrey Neale; Sarah Thomas; Deepa Nachagari; Peter Vogel; Mary Vore; Frank J Gonzalez; John D Schuetz
Journal:  J Biol Chem       Date:  2012-05-22       Impact factor: 5.157

5.  Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor.

Authors:  M Ananthanarayanan; N Balasubramanian; M Makishima; D J Mangelsdorf; F J Suchy
Journal:  J Biol Chem       Date:  2001-05-31       Impact factor: 5.157

Review 6.  Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease.

Authors:  Akshay Shetty; WonKyung Cho; William Alazawi; Wing-Kin Syn
Journal:  Am J Med Sci       Date:  2017-03-14       Impact factor: 2.378

7.  Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study.

Authors:  Harold Nelson; James Kemp; William Berger; Jonathon Corren; Thomas Casale; Louise Dube; Karen Walton-Bowen; Nicole LaVallee; Miganush Stepanians
Journal:  Ann Allergy Asthma Immunol       Date:  2007-08       Impact factor: 6.347

8.  Dysregulation of protein degradation pathways may mediate the liver injury and phospholipidosis associated with a cationic amphiphilic antibiotic drug.

Authors:  Merrie Mosedale; Hong Wu; C Lisa Kurtz; Stephen P Schmidt; Karissa Adkins; Alison H Harrill
Journal:  Toxicol Appl Pharmacol       Date:  2014-06-23       Impact factor: 4.219

9.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.

Authors:  Mitsuhiro Watanabe; Sander M Houten; Li Wang; Antonio Moschetta; David J Mangelsdorf; Richard A Heyman; David D Moore; Johan Auwerx
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

Review 10.  Role of mitochondria in nonalcoholic fatty liver disease.

Authors:  Fatiha Nassir; Jamal A Ibdah
Journal:  Int J Mol Sci       Date:  2014-05-15       Impact factor: 5.923

View more
  2 in total

Review 1.  Model systems and organisms for addressing inter- and intra-species variability in risk assessment.

Authors:  Ivan Rusyn; Weihsueh A Chiu; Fred A Wright
Journal:  Regul Toxicol Pharmacol       Date:  2022-05-28       Impact factor: 3.598

Review 2.  Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases.

Authors:  Jin-Nan Wu; Jian-Rong Chen; Jin-Liang Chen
Journal:  Can Respir J       Date:  2020-11-26       Impact factor: 2.409

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.